Pricing and Reimbursement of Orphan Drugs: The Need for More Transparency

Orphanet Journal of Rare Diseases - United Kingdom
doi 10.1186/1750-1172-6-42
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

The Need for Transparency and Efficiency in Reimbursement Decisions Relating to Drugs for Rare Diseases

Medical Decision Making
Health Policy
2014English

Reimbursement Decision Landscape for Orphan Drugs Across Six Hta Agencies

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Reimbursement of Orphan Drugs: The Pompe and Fabry Case in the Netherlands

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2014English

Psy147 - Availability and Reimbursement of Orphan Drugs in the Czech Republic

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Reimbursement of Orphan Drugs in Belgium: What (Else) Matters?

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2014English

Pcp37 - The Confidentiality Regarding Drugs Pricing and Reimbursement in Romania

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Php140 - Current Challenges and Potential Solution for Pricing Regulatory and Reimbursement Framework of Innovative Drugs in Egypt

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Php359 - Impact of Expedited Marketing Authorisation on Pricing and Reimbursement Outcomes for Drugs in the Us and Eu-5

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost-Information Transparency and Intertemporal Pricing

SSRN Electronic Journal
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy